Systemic sclerosis & Raynaud's
Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study
Authors' conclusion
This study suggests that antibodies targeting Ro52 are enriched in the lungs of patients with new-onset SSc-ILD, linking Ro52 autoimmunity to the pulmonary pathology of SSc.
Study context
- Population
- Patients with new-onset or early SSc-ILDlongitudinal cohort
- Participants
- 43 patients
- Exposure
- Anti-Ro52 positive vs anti-Ro52 negative; anti-Scl-70 positive vs negative
- Anti-Ro52n = 10
- Anti-Scl-70n = 16
- Outcome
- Loss of lung function over time (%pVC/year)
Methodological detailslongitudinal cohort, linear mixed effect models, bronchoalveolar lavage (BAL) and serum autoantibody analysis, immunohistochemistry
- Longitudinal cohort
- Linear mixed effect models
- BAL and serum autoantibody analysis
- Immunohistochemistry
Main finding
As reported in the abstract
Loss of lung function over time (%pVC/year), longitudinal cohort
Association with loss of lung function
−2.41 %pVC/year
95% CI −4.28 to −0.54P = 0.013
Anti-Ro52
Association with loss of lung function
−1.07 %pVC/year
95% CI −2.86 to 0.71P = 0.230
Anti-Scl-70 · not significantly associated
Observational data: associations, not effects.
Further findings
| Outcome | Change per arbitrary units/mL and year (%pVC per arbitrary units/mL and year) (95% CI) | P value | |
|---|---|---|---|
| Rate of loss of lung function per anti-Ro52 antibody levelIncreased linearly with increasing levels | −0.03 (−0.05 to −0.02) | P < 0.001 | |
| −0.06−0.04−0.0200.02Difference, %pVC per arbitrary units/mL and year (linear scale) |
| Outcome | Association with VC (% predicted VC) (95% CI) | P value |
|---|---|---|
| VC at baseline (%pVC) | −12.6 (−25.0 to −0.29) | P = 0.045 |
- Enrichment of anti-Ro52 in BAL fluid (ratio >50x) among anti-Ro52-positive new-onset SSc-ILD
- 60% · 3
- Enrichment of anti-Ro52 in BAL fluid (ratio >50x) among anti-Ro52-positive new-onset SSc-ILD: N = 5 anti-Ro52 positive
Original publication
Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study. Arthritis Res Ther. Published 4 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →